/-->Menu
Search
Home > Courses > Best of ACTHIV: Initial Treatment for a Person with HIV Infection

Best of ACTHIV: Initial Treatment for a Person with HIV Infection

Best of ACTHIV: Initial Treatment for a Person with HIV Infection
Play
Sorry, this learning module is not available for mobile devices.
ACTHIV
Original Release Date: 9/15/2019
Termination Date: 09/15/2020
Review Date: 9/15/2019
Presenter
  • Rajesh T. Gandhi, MD
    Associate Professor of Medicine
    Harvard Medical School
Learning Objectives / Desired Outcomes
At the completion of this educational activity, participants will:
  1. Individualize initial antiretroviral therapy for a person with HIV infection
  2. Evaluate new options for treating HIV
Presenter Bio
Rajesh T. Gandhi, MD
Dr. Gandhi is Associate Professor of Medicine at Harvard Medical School, and the Director of HIV Clinical Services and Education at Massachusetts General Hospital (MGH). Dr. Gandhi is site leader of the MGH AIDS Clinical Research Site in the Harvard/Miriam AIDS Clinical Trials Unit (ACTU) and vice-chair of the AIDS Clinical Trials Group HIV-1 Reservoirs and Eradication Transformative Science Group. He is also the Director of the Harvard University Center for AIDS Research Clinical Core. Dr. Gandhi is the editor of Partners ID Images, an educational infectious diseases website, and organizer of the HIV Online Provider Education (HOPE) program, an internet-based educational conference series for physicians caring for HIV patients in resource-limited settings. His research interests include clinical trials of immune-based therapies for HIV, HIV reservoirs, and HIV/viral hepatitis coinfections.
Continuing Education Credit

The enduring material is jointly provided by Beaumont Health, American Academy of CME, Inc., and the American Conference for the Treatment of HIV (ACTHIV).

The 13th Annual American Conference for the Treatment of HIV (ACTHIV) was held April 11-13, 2019 in Miami, FL. The Conference was supported by the Clinical Education Initiative, New York State Department of Health, AIDS Institute. The conference and this web archive were supported by educational grants from Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; Merck & Co., and ViiV HealthCare.

ONLINE CE CREDIT:

To obtain online CE credit, please follow this link to the course evaluation and follow the instructions.

FACULTY:
Rajesh T. Gandhi, MD, is a Professor of Medicine at Harvard Medical School, and the Director of HIV Clinical Services and Education at Massachusetts General Hospital.

Estimated time to complete: 30 minutes

TARGET AUDIENCE
Members of the HIV care team who are frontline providers of care to persons at risk of or with HIV infection, including physicians (both specialists and primary care/family medicine), nurse practitioners, physician assistants, nurses. Pharmacists, case managers and other healthcare professionals are also encouraged to participate.

Learning Objectives/Learning Outcomes
As a result of participating in this activity, participants should be better able to:

  • Individualize initial antiretroviral therapy for a person with HIV infection
  • Evaluate new options for treating HIV

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Beaumont Health, American Academy of CME, Inc., and the American Conference for the Treatment of HIV (ACTHIV). Beaumont Health is accredited by the ACCME to provide continuing medical education for physicians.

Physicians:

Beaumont Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACTHIVIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc., Beaumont Health, and the American Conference for the Treatment of HIV (ACTHIV). American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses Practitioners and Nurses:

American Academy of CME, Inc. designates this educational activity for 0.5 contact hours (0.4 pharmacotherapeutic contact hours).

Physician Assistants:

American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until September 15, 2020. PAs should only claim credit commensurate with the extent of their participation.

All other members of the HIV Care team will receive a certificate of participation.

There is no fee to participate in this activity.

HOW TO RECEIVE CREDIT

In order to obtain your certificate of credit, you must read the CME/CE information, review the full content of the activity, and complete the evaluation.

Upon submission of the evaluation, your certificate for the activity will be made available immediately to print online.

DISCLOSURES

According to the disclosure policy of the Academy and Beaumont, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures will be made known to the participants prior to the activity.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy, Beaumont, or ACTHIV. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Off-Label Usage Disclosure

This activity may contain off-label discussion.

Faculty Disclosure

Dr. Gandhi disclosed the following relationships: Advisory Board: Gilead Sciences, Merck & Co., Theratechnologies; Grant/Research Support: Gilead Sciences, Janssen Therapeutics, Merck & Co., Theratechnologies, ViiV Healthcare.

Planner Disclosures

The following planners have no relevant financial relationships with commercial interests to disclose: John Brooks, MD; Sherrillyn Crooks, PA-C; John Juchniewicz, MCIS, CHCP; Bill Kapogiannis, MD; H. Nina Kim, MD; Natalie Kirkwood, RN, BSN, JD; Harry Lampiris, MD; Sharon Lee, MD; Vincent Lo Re, MD, MSCE; Lorenzo McFarland, DHA, MPH, MSW, PMP; Edward Moylan, RP; Asa Radix, MD, MPH; Dianne Rausch, PhD; Renslow Sherer, MD; Cheryl Smith, MD; Brooke Taylor, MPH, CHCP; Barbara Young, MSW, LCSE, LCADC, SAC.

The following planners have disclosed financial relationships with commercial interests:

Oluwatoyin Adeyemi, MD: Advisory Board: Gilead Sciences; Grant/Research Support: AbbVie, Gilead Sciences
Roger Bedimo, MD, MS: Advisory Board: Gilead Sciences, Merck & Co., ViiV Healthcare; Grant/Research Support: Merck & Co., ViiV Healthcare
Michelle Cespedes, MD, MS: Advisory Board: Gilead Sciences
Eric Daar, MD: Advisory Board: Gilead Sciences, Merck & Co., ViiV Healthcare; Consultant: Gilead Sciences, Merck & Co., Theratechnologies, ViiV Healthcare; Grant/Research Support: Gilead Sciences, Merck & Co., ViiV Healthcare
Carlos del Rio, MD: Consultant: ViiV Healthcare
Courtney Fletcher, PharmD: Advisory Board: Merck & Co.
Donna Futterman, MD: Grant/Research Support: Gilead Sciences
Rajesh Gandhi, MD: Advisory Board: Gilead Sciences, Merck & Co., Theratechnologies; Grant/Research Support: Gilead Sciences, Janssen Therapeutics, Merck & Co., Theratechnologies, ViiV Healthcare
Margaret Hoffman-Terry, MD, FACP, AAHIVS: Advisory Board: Gilead Sciences, Merck & Co., ViiV Healthcare; Consultant: Gilead Sciences, ViiV Healthcare; Grant/Research Support: ViiV Healthcare; Promotional Speaker’s Bureau: Gilead Sciences, Merck & Co.
Tonia Poteat, PhD, MPH, PA-C: Grant/Research Support: Gilead Sciences, ViiV Healthcare
William Short, MD, MPH: Advisory Board: Gilead Sciences, ViiV Healthcare; Consultant: Gilead Sciences; Promotional Speaker’s Bureau: Janssen Therapeutics
Pablo Tebas, MD: Advisory Board: Gilead Sciences, Merck & Co., ViiV Healthcare; Consultant: Gilead Sciences, Merck & Co., ViiV Healthcare; Grant/Research Support: Gilead Sciences, Genone, Inovio, Janssen Therapeutics, Merck & Co., ViiV Healthcare
Melanie Thompson, MD: Grant/Research Support: Bristol-Myers Squibb, CytoDyn, Frontier Biotechnologies, Gilead Sciences, GlaxoSmithKline Merck Sharp & Dohme, Roche Molecular Systems, TaiMed, ViiV Healthcare
Andrea Weddle, MSW: Speaker (Public Policy Event): ViiV Healthcare
Susan Weiss, MSN, FNP: Advisory Board: Gilead Sciences, Merck & Co., Theratechnologies; Consultant: Gilead Sciences, Janssen Therapeutics, Merck & Co., ViiV Healthcare; Promotional Speaker’s Bureau: Gilead Sciences, Janssen Therapeutics, ViiV Healthcare
Ronald Wilcox, MD: Advisory Board: Napo Pharmaceuticals.

Privacy Policy
For more information about Beaumont's privacy policy, please access https://www.beaumont.org/patients-families/patients-rights-privacy/privacy
For more information about the Academy's privacy policy, please access http://www.academycme.org/privacy.htm

For questions related to physician credit, contact: cme@beaumont.edu

For questions related to nursing (including NPs) and PA credit, contact: CEServices@academycme.org

Hardware/Software Requirements To access this activity hardware and software requirements are noted below.

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later

Copyright 2019. American Academy of CME, Inc., Beaumont Health, and American Conference for the Treatment of HIV.

Resources: